Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$70.27 USD
+1.80 (2.63%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.27 USD
+1.80 (2.63%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Zacks News
OPKO Health (OPK) Q3 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.
CVS Health (CVS) Beats on Q3 Earnings, Raises '19 EPS Guidance
by Zacks Equity Research
CVS Health's (CVS) strong year-over-year growth in the top line is aided by a robust performance at the Pharmacy Services segment.
HMS Holdings (HMSY) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
HMS Holdings' (HMSY) Q3 earnings benefit from higher revenues at Analytical Services unit and strong 2019 outlook.
Avanos (AVNS) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Avanos (AVNS) third-quarter results benefit from higher revenues and strong segmental performance.
Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.
DaVita (DVA) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DaVita (DVA) raises guidance for 2019 following impressive Q3 results.
STERIS' (STE) Q2 Earnings Surpass Estimates, FY20 View Up
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in the second quarter of fiscal 2020.
Allscripts (MDRX) Q3 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Allscripts (MDRX) third-quarter results gain from growth in bookings and solid segmental performance. Contraction in both gross and operating margins remains a woe.
Luminex (LMNX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Luminex's (LMNX) Q3 earnings benefit from higher revenues and solid performance across System Sales, Consumable Sales and Service Revenues. However, gross margin contraction remains a woe.
Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) observes a decline in Hereditary Cancer, GeneSight, Vectra as well as Other testing revenues in Q1.
Henry Schein (HSIC) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Henry Schein (HSIC) registers solid performance across its key operating businesses in Q3.
Becton, Dickinson (BDX) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental contributions in Q4.
Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More
by Urmimala Biswas
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.
Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.
Bio-Rad (Bio) Q3 Earnings Beat Estimates on All-Line Growth
by Zacks Equity Research
Growing strength in many of Bio-Rad's (Bio) key product lines across major geographic regions buoys investors' optimism on the stock.
Integer Holdings (ITGR) Beats on Q3 Earnings, Revenues Miss
by Zacks Equity Research
Integer Holdings' (ITGR) Q3 earnings benefit from higher revenues and strong 2019 outlook.
PRA Health (PRAH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health (PRAH) raises 2019 EPS view after a solid third-quarter show.
AMN Healthcare (AMN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Nurse and Allied Solutions segment drives AMN Healthcare's (AMN) third-quarter results.
Teleflex (TFX) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
We are encouraged by Teleflex's (TFX) robust improvement in Q3 revenues on balanced growth across majority of segments and all geographies.
NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
We are encouraged to note that NuVasive (NUVA) witnessed solid revenue growth across its U.S. Spinal Hardware business in Q3.
Amedisys (AMED) Q3 Earnings Beat Estimates, Revenues Meet
by Zacks Equity Research
Amedisys (AMED) continues to witness solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.
IDEXX (IDXX) Tops Q3 Earnings Estimates, Lowers EPS View
by Zacks Equity Research
IDEXX (IDXX) impresses investors with solid third-quarter 2019 results on robust performance across all business segments.
CONMED (CNMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) Q3 earnings gain from higher revenues, solid segmental performance and margin expansion. However, high long-term debt remains a concern.
Merit Medical (MMSI) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Merit Medical's (MMSI) Q3 earnings gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.
PerkinElmer (PKI) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
PerkinElmer's (PKI) Q3 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.